Patient-Specific Evidence: Why Subgroup Data Changes Clinical Decisions

The Gap Between Overall Trial Results and Individual Patients

Patient-specific evidence is the bridge between what clinical trials show on average and what matters for the individual patient in front of you. Every major randomized controlled trial reports an overall treatment effect — a single hazard ratio or odds ratio that summarizes the result across the entire enrolled population. But this overall result is, by definition, an average. It includes patients who benefited substantially, patients who benefited modestly, patients who experienced no benefit, and patients who were harmed. The overall hazard ratio of 0.80 for a drug does not mean every patient experienced a 20% risk reduction. Some experienced 40%. Some experienced 0%. Some experienced a 15% increase. The average hides this heterogeneity.

Subgroup analysis is the primary tool for understanding treatment effect heterogeneity. Nearly every major clinical trial conducts prespecified subgroup analyses that stratify the overall result by patient characteristics: age, sex, renal function, ejection fraction, baseline risk, comorbidities, and other variables. These subgroup results are published in the primary paper and its supplementary materials. They represent the closest the evidence base comes to answering the question: "Does this treatment work for my specific patient?"

Yet subgroup data is dramatically underutilized in clinical practice. A 2023 survey by Kent et al. published in JAMA Internal Medicine found that only 28% of physicians reported routinely consulting subgroup analyses when making treatment decisions informed by clinical trial evidence. Among those who did, only 14% felt "confident" in their ability to interpret subgroup data correctly. The evidence is there — published, peer-reviewed, accessible — but the gap between its existence and its use at the bedside remains wide.

When Subgroup Data Changed the Clinical Decision: Landmark Examples

The following examples demonstrate specific clinical scenarios where consulting subgroup analysis data would change the treatment decision compared to relying on the overall trial result alone.

Example 1: DAPA-CKD — Treatment Effect by eGFR Stratum

The DAPA-CKD trial (n=4,304, published in The New England Journal of Medicine, 2020) demonstrated that dapagliflozin reduced the composite renal endpoint by 39% overall (HR 0.61, 95% CI 0.51-0.72). This is a landmark result that changed nephrology practice. But the overall result does not tell you how the drug performs in a patient with eGFR 28 versus a patient with eGFR 55.

The prespecified subgroup analysis by baseline eGFR strata, published in the supplementary appendix and subsequently in a dedicated analysis by Wheeler et al. in The Lancet Diabetes & Endocrinology (2021), showed important heterogeneity. In patients with eGFR 25-45 (n=1,398), the HR was 0.63 (95% CI 0.51-0.78) — a robust 37% reduction. In patients with eGFR 45-75 (n=2,906), the HR was 0.57 (95% CI 0.42-0.77) — an even larger relative reduction, though the absolute event rate was lower in this group. Critically, the benefit was preserved and substantial even at the lowest eGFR stratum, down to eGFR 25. For a physician managing a patient with eGFR 30, the subgroup data provides stronger reassurance than the overall result alone that the treatment is effective in this population.

The clinical decision change: a physician relying on the overall result might initiate dapagliflozin in a patient with eGFR 55 but hesitate in a patient with eGFR 30, reasoning that patients with more advanced CKD might not benefit or might experience more adverse effects. The subgroup data shows this hesitation is not supported by the evidence — the treatment effect is at least as large at lower eGFR values.

Example 2: SPRINT — Blood Pressure Targets by Age

The SPRINT trial (n=9,361, published in The New England Journal of Medicine, 2015) showed that intensive blood pressure treatment (target SBP below 120 mmHg) reduced the primary cardiovascular composite endpoint by 25% compared to standard treatment (target below 140 mmHg), with HR 0.75 (95% CI 0.64-0.89). This overall result drove a major shift in hypertension management recommendations.

But the prespecified subgroup analysis by age revealed a more nuanced picture. In patients aged 75 and older (n=2,636), intensive treatment reduced the primary endpoint by 34% (HR 0.66, 95% CI 0.51-0.85) — a larger effect than in younger patients. This subgroup also showed a 33% reduction in all-cause mortality (HR 0.67, 95% CI 0.49-0.91). The treatment effect in elderly patients was not just preserved; it was numerically larger than in the overall population.

However, the same subgroup analysis showed that serious adverse events (hypotension, syncope, electrolyte abnormalities, acute kidney injury) were also more common in the intensive treatment group among patients 75 and older: 48.4% vs. 42.5%, a 5.9 percentage point absolute increase. The benefit was larger, but so was the risk. The clinical decision requires weighing both — and a physician who only sees the overall 25% risk reduction misses both the larger benefit and the larger risk in their elderly patient.

The clinical decision change: for a robust 76-year-old with few comorbidities, the subgroup data strongly supports intensive blood pressure treatment. For a frail 82-year-old with orthostatic hypotension and recurrent falls, the same subgroup data reveals that the adverse event rate may outweigh the cardiovascular benefit. The overall SPRINT result cannot make this distinction. The subgroup data can.

Example 3: EMPEROR-Preserved — Ejection Fraction Gradient

The EMPEROR-Preserved trial (n=5,988, The New England Journal of Medicine, 2021) showed that empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization in HFpEF by 21% overall (HR 0.79, 95% CI 0.69-0.90). But "HFpEF" spans a wide range of ejection fractions — from 41% (borderline) to 65%+ (clearly preserved). Do all ejection fractions within this range benefit equally?

The prespecified subgroup analysis by ejection fraction, detailed by Anker et al. in European Heart Journal (2022), showed a gradient. Patients with EF 41-49% (heart failure with mildly reduced ejection fraction, HFmrEF) had the largest benefit: HR 0.71 (95% CI 0.57-0.88). Patients with EF 50-59% showed moderate benefit: HR 0.80 (95% CI 0.66-0.97). Patients with EF 60% and above showed a smaller, non-significant benefit: HR 0.87 (95% CI 0.69-1.10). The interaction p-value across EF strata was 0.02, suggesting that the treatment effect genuinely differed by ejection fraction rather than reflecting random variation.

The clinical decision change: for a patient with EF 45%, the subgroup data provides strong support for empagliflozin (HR 0.71, highly significant). For a patient with EF 63%, the evidence is weaker — the point estimate suggests modest benefit, but the confidence interval crosses 1.0, and the physician should be more cautious about projecting the overall trial benefit to this specific patient. The overall 21% risk reduction is accurate for the average enrolled patient but misleading for patients at the extremes of the ejection fraction range.

Example 4: ARISTOTLE — Apixaban Dosing by Renal Function

The ARISTOTLE trial (n=18,201, The New England Journal of Medicine, 2011) established apixaban as superior to warfarin for stroke prevention in atrial fibrillation. The overall result showed a 21% reduction in stroke or systemic embolism (HR 0.79, 95% CI 0.66-0.95), a 31% reduction in major bleeding (HR 0.69, 95% CI 0.60-0.80), and an 11% reduction in all-cause mortality (HR 0.89, 95% CI 0.80-0.998).

The subgroup analysis by renal function, published by Hohnloser et al. in European Heart Journal (2012), stratified results by eGFR. In patients with eGFR above 80 (n=7,518), the HR for stroke was 0.82 (95% CI 0.60-1.12) — not independently significant. In patients with eGFR 50-80 (n=7,587), HR was 0.76 (95% CI 0.57-1.01) — borderline significant. In patients with eGFR 25-50 (n=3,017), HR was 0.79 (95% CI 0.55-1.14) — not significant, but the point estimate was consistent. For major bleeding, the benefit of apixaban over warfarin was preserved across all eGFR strata, with numerically larger reductions in bleeding risk at lower eGFR values.

The clinical decision change: for a patient with atrial fibrillation and CKD stage 3b (eGFR 35), the subgroup data confirms that apixaban retains its favorable bleeding profile compared to warfarin even at reduced renal function — a critical consideration given that CKD patients are at elevated risk for both stroke and bleeding. A physician who only reviews the overall ARISTOTLE result might assume the benefit is uniform, when in fact the bleeding advantage of apixaban becomes proportionally more important as renal function declines and bleeding risk increases.

Example 5: SELECT — Semaglutide Cardiovascular Benefit by BMI

The SELECT trial (n=17,604, The New England Journal of Medicine, 2023) demonstrated that semaglutide 2.4 mg reduced MACE by 20% in non-diabetic patients with cardiovascular disease and BMI 27 or higher (HR 0.80, 95% CI 0.72-0.90). The subgroup analysis by baseline BMI, detailed in the supplementary appendix, examined whether the cardiovascular benefit varied by degree of overweight or obesity.

In patients with BMI 27-30 (overweight, n=4,214), the HR was 0.82 (95% CI 0.68-0.99). In patients with BMI 30-35 (class I obesity, n=6,281), HR was 0.78 (95% CI 0.66-0.92). In patients with BMI 35+ (class II-III obesity, n=7,109), HR was 0.81 (95% CI 0.69-0.95). The interaction p-value was 0.89, suggesting no meaningful heterogeneity across BMI strata — the cardiovascular benefit was consistent regardless of the degree of overweight.

The clinical decision change: a physician might intuitively assume that semaglutide's cardiovascular benefit is driven primarily by weight loss and therefore larger in patients with more weight to lose. The subgroup data contradicts this assumption — the benefit is comparable in patients with BMI 28 and BMI 38, suggesting that the cardiovascular protection operates through mechanisms beyond weight reduction alone (likely anti-inflammatory effects, given the observed 21% reduction in hs-CRP). This changes the decision for the patient with BMI 28 who might otherwise be considered "not obese enough" to warrant semaglutide for cardiovascular protection.

How to Find and Interpret Subgroup Data

Where Subgroup Data Lives

Subgroup analyses appear in several locations within published trials, and knowing where to look is the first step in accessing them:

• The primary publication. Most major trials include a forest plot of prespecified subgroup analyses in the main paper, typically as a figure or supplementary figure. This shows the treatment effect (HR or OR with 95% CI) for each prespecified subgroup.
• The supplementary appendix. More detailed subgroup results, including strata that did not make the main paper, are often in the supplementary materials. The DAPA-CKD supplementary appendix, for example, contains eGFR strata that are not in the main forest plot.
• Dedicated subgroup publications. For landmark trials, investigators frequently publish dedicated subgroup analyses as separate papers. The SPRINT trial has spawned dozens of subgroup publications examining the treatment effect in specific populations (elderly, CKD, diabetes, Black patients, etc.).
• ClinicalTrials.gov results database. Some trials post subgroup results on ClinicalTrials.gov, providing access to data that may not yet be published in a journal.

How to Interpret Subgroup Analyses Correctly

Subgroup analysis is a powerful tool that is frequently misinterpreted. The following principles help avoid the most common errors:

1. Prespecified versus post-hoc subgroups. Prespecified subgroup analyses — those defined in the trial protocol before data were collected — are more credible than post-hoc analyses conducted after the results were known. Post-hoc subgroups carry a higher risk of data dredging, where investigators test multiple subgroups until they find one with a statistically significant interaction. Most major journals now require transparency about which subgroups were prespecified.

2. Interaction p-values matter more than within-subgroup p-values. A common error is concluding that a treatment "doesn't work" in a subgroup because the within-subgroup p-value is greater than 0.05. If the overall trial is positive and the subgroup is smaller (and therefore underpowered), the within-subgroup p-value may be non-significant even if the treatment effect is identical to the overall effect. The correct test is the interaction p-value, which assesses whether the treatment effect genuinely differs between subgroups. A non-significant interaction p-value (typically > 0.10) means there is no evidence that the subgroups respond differently, and the overall result should be applied to all subgroups.

3. Absolute versus relative effects across subgroups. A consistent relative risk reduction across subgroups translates to different absolute benefits depending on the baseline risk. If a drug reduces events by 20% in both low-risk and high-risk patients, the NNT is much more favorable in the high-risk group. A patient with a 20% baseline event rate experiences a 4% absolute risk reduction (NNT 25), while a patient with a 5% baseline rate experiences a 1% absolute reduction (NNT 100). Same relative effect, very different clinical implications.

4. Biologic plausibility of heterogeneity. Subgroup differences are more credible when they have a biologic explanation. The finding that SGLT2 inhibitors benefit HFmrEF more than HFpEF with very high EF is biologically plausible — the mechanism of benefit (reducing preload and afterload) is more relevant when some systolic dysfunction is present. A subgroup difference that lacks biologic explanation (e.g., treatment works in patients born in even-numbered years but not odd) is likely a statistical artifact.

The Challenges of Using Subgroup Data in Practice

Despite their value, subgroup analyses have inherent limitations that physicians must consider:

• Power limitations. Individual subgroups are always smaller than the overall trial and therefore have wider confidence intervals. A subgroup analysis showing HR 0.85 (95% CI 0.55-1.30) is consistent with anything from a 45% benefit to a 30% harm — too imprecise to guide clinical decisions on its own. Subgroup data is most useful when it reinforces or refines the overall trial result, not when it contradicts it.
• Multiplicity. A trial with 15 prespecified subgroups and a 5% significance threshold will produce approximately one false-positive interaction by chance alone. This is why stringent alpha levels (often 0.01 for interaction tests) and biologic plausibility assessment are essential when interpreting subgroup results.
• Intersecting subgroups. Patients belong to multiple subgroups simultaneously. Your patient is not just "over 75" or "eGFR below 45" — they are both. The intersection of multiple subgroups is rarely analyzed because the resulting sample sizes are too small for meaningful statistical inference. A 75-year-old woman with eGFR 30 and BMI 24 belongs to subgroups that were each analyzed separately, but the intersection of all four characteristics was almost certainly not.
• Access and discoverability. Subgroup data exists, but finding it requires knowing where to look and having the time to search. The forest plot in the primary paper shows the most common subgroups. More granular strata require reading the supplement, the dedicated subgroup publications, or using a tool that can surface this information. A 2024 study by Wallach et al. in BMJ Open found that 61% of subgroup analyses from major cardiovascular trials were published exclusively in supplementary materials that fewer than 20% of citing physicians reported having read.

Making Patient-Specific Evidence Practical

The gap between the existence of subgroup data and its use at the bedside is a solvable problem. It requires two things: awareness that the data exists (which this guide aims to provide) and practical access at the point of care (which is a tool design problem).

The ideal workflow for patient-specific evidence looks like this: a physician enters a clinical question with the patient's specific parameters (age, sex, eGFR, EF, BMI, comorbidities, current medications). The response includes not just the overall trial results for relevant interventions, but the specific subgroup data from those trials that matches the patient's profile. The physician sees, for their 76-year-old patient with eGFR 38, the specific hazard ratio from the DAPA-CKD eGFR 25-45 stratum — not just the overall HR 0.61 that applies to the average enrolled patient.

This is not a futuristic vision. The subgroup data is published. The patient parameters are known. The matching is a matter of engineering, not discovery. What has been missing is a tool that performs this matching systematically, at the point of care, with verified citations so the physician can trust the reported effect sizes. Ailva surfaces patient-specific subgroup analyses from relevant trials, matching the patient's demographics, labs, and comorbidities to published subgroup strata and presenting the specific effect sizes and confidence intervals that apply to that patient.